Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2026 08:30 ET | Source: NovelMed Therapeutics Inc

NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH

--- Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration Key Highlights: Monotherapy and Clinical Outcomes The...